The Oncotype DX Breast Recurrence® test provides significant value in clinical practice
For node-negative, early-stage breast cancer patients
The Oncotype DX Breast Recurrence Score test is the only test validated to predict chemotherapy benefit for your patients with HR+, HER2-, node-negative, early-stage, invasive breast cancer and help to guide treatment decisions.1–4
TAILORx and NSABP B-20 results show that most patients do not benefit from chemotherapy2,3
How does the Oncotype DX® test help guide treatment decisions?
Clinical evidence has demonstrated:
- Patients with Recurrence Score® results 0–25 do not benefit from the addition of chemotherapy to endocrine therapy1–4
- Patients with Recurrence Score results 26–100 derive a 26% absolute benefit (group average) from the addition of chemotherapy to endocrine therapy3
- An exploratory analysis suggests that patients ≤50 years of age with Recurrence Score results 16–25 may benefit from chemotherapy2,4
-
Guiding Treatment Based on Recurrence Score Results and Age
How can the Oncotype DX test help reduce the risk of over- and undertreatment?
Clinical risk features alone (tumour size, grade, clinical risk category) are proven to be prognostic-only and insufficient to determine chemotherapy benefit2
Exploratory analyses were performed to evaluate whether subgroups may derive benefit from the addition of chemotherapy to endocrine therapy in patients with Recurrence Score results 11–252
The Oncotype DX test can help reduce risks of over- and undertreatment2
73% of patients with high clinical risk had Recurrence Score results 0-25 and may have been overtreated if decisions had been made without the Oncotype DX test
HIGH CLINICAL RISK PATIENTS
Chemotherapy can potentially be spared
43% of patients with Recurrence Score results 26-100 had low clinical risk and may have been undertreated if decisions had been made without the Oncotype DX test
LOW CLINICAL RISK PATIENTS
Chemotherapy can potentially be life-saving
a Low clinical risk defined by low grade and tumour size ≤3 cm, intermediate grade and tumour size ≤2 cm, and high grade and tumour size ≤1 cm; high clinical risk defined as all other cases with known values for grade and tumour size
PROVEN CLINICAL UTILITY OF THE ONCOTYPE DX TEST1–3
Adjuvant chemotherapy may be guided with the Oncotype DX Breast Recurrence Score test to identify:
- the majority of patients with no chemotherapy benefit
- the patients for whom chemotherapy may be life-saving
The Oncotype DX Breast Recurrence Score test is the standard of care to guide adjuvant treatment in HR+, HER2–, early-stage breast cancer, for both node-negative and node-positive patients5-10
Since clinical risk features alone are not sufficient to determine CT benefit, the Oncotype DX Breast Recurrence Score test should be used for2,16:
- All patients for whom chemotherapy may be spared
- All patients for whom chemotherapy may be life-saving
-
REFERENCES